An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
DermTech Announces the Foundational Assay of Its DermTech Melanoma Test (DMT) Is Recommended for Coverage by the Veterans Health Administration
Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
DermTech, a leader in non-invasive skin genomics, has received a positive coverage recommendation from the U.S. General Services Administration for its foundational assay in the DermTech Melanoma Test (DMT). This recommendation will make the test accessible to over 9 million Veterans enrolled in the Veterans Health Administration (VHA), the largest integrated healthcare system in the U.S. The DMT features an impressive 99% negative predictive value, enhancing melanoma detection. DermTech's covered lives now total approximately 124 million, including Medicare and commercial payers, positioning the company for potential growth in the precision dermatology sector.
Positive
VHA recommends DermTech's melanoma test for coverage, increasing access to over 9 million Veterans.
The DMT test has a greater than 99% negative predictive value, enhancing melanoma detection accuracy.
DermTech's total covered lives reached approximately 124 million, including 68 million for Medicare.
Negative
None.
LA JOLLA, Calif.--(BUSINESS WIRE)--
DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced that U.S. General Services Administration has recommended the Company’s foundational assay included in the DermTech Melanoma Test (DMT) for coverage by the Veterans Health Administration (VHA). The VHA is the largest integrated health care system in the U.S. providing care at 1,298 health care facilities.
This coverage recommendation makes the foundational assay of the DMT available to the VHA’s over 9 million enrolled Veterans. The DMT is an innovative, non-invasive way to enhance melanoma detection with a greater than 99 percent negative predictive value (NPV).
“We’re honored to join the VHA in bringing our non-invasive melanoma test to America’s Veterans,” said Dan Visage, senior vice president of payor access, DermTech. “The DMT test results are clinically meaningful and actionable, improve patient care and reduce healthcare costs. We look forward to teaming up with the VHA to make our test widely available to its beneficiaries in the coming months.”
DermTech’s total covered lives in the U.S. are now approximately 124 million, which includes 68 million for Medicare/Medicare Advantage and 56 million for commercial and governmental payers.
About The DermTech Melanoma Test
DermTech originally marketed its foundational assay under the name Pigmented Lesion Assay (PLA). The PLA assesses pigmented skin lesions, moles or dark skin spots for melanoma. In particular, the PLA detects expression of the LINC00518 (LINC) and preferentially expressed antigen in melanoma (PRAME) genes using reverse transcription-polymerase chain reaction (RT-PCR). The Company introduced its second-generation test in 2021 as an add-on assay to PLA, which is designed to identify the presence of mutations in TERT gene promoter region using DNA sequencing. The Company has since branded its PLA and TERT add-on-assay as the DermTech Melanoma Test (DMT). The DMT may be ordered with or without the add-on test for TERT. Positive results for LINC, PRAME or TERT correlate with a lesion at higher risk for melanoma. If none of the biomarkers are detected, this result indicates a greater than 99% probability that the mole being tested is not melanoma.
About DermTech
DermTech is a leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by its non-invasive skin genomics platform. DermTech’s mission is to improve the lives of millions by providing non-invasive precision dermatology solutions that enable individualized care. DermTech provides genomic analysis of skin samples collected non-invasively using our Smart StickersTM. DermTech markets and develops products that facilitate the early detection of skin cancers and is developing products that assess inflammatory diseases and customize drug treatments. For additional information, please visit DermTech.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from its actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” "outlook," “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations and evaluations with respect to: the performance, patient benefits, cost- effectiveness, commercialization and adoption of DermTech’s products and the market opportunity for these products, DermTech’s positioning and potential revenue growth, financial outlook and future financial performance, ability to maintain or improve its operating efficiency and reduce operating expenses, implications and interpretations of any study results, expectations regarding agreements with or reimbursement or cash collection patterns from Medicare or commercial payers and related billing practices or number of covered lives, and DermTech’s ability to expand its product offerings and develop pipeline products. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of DermTech and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against DermTech; (2) DermTech’s ability to obtain additional funding to develop and market its products; (3) the existence of favorable or unfavorable clinical guidelines for DermTech’s tests; (4) the reimbursement of DermTech’s tests by Medicare and commercial payers; (5) the ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for DermTech’s products; (6) DermTech’s ability to grow, manage growth and retain its key employees and maintain or improve its operating efficiency and reduce operating expenses; (7) changes in applicable laws or regulations; (8) the market adoption and demand for DermTech’s products and services together with the possibility that DermTech may be adversely affected by other economic, business, and/or competitive factors; and (9) other risks and uncertainties included in the “Risk Factors” section of the most recent Annual Report on Form 10-K filed by DermTech with the Securities and Exchange Commission (the “SEC”), and other documents filed or to be filed by DermTech with the SEC, including subsequently filed reports. DermTech cautions that the foregoing list of factors is not exclusive. You should not place undue reliance upon any forward- looking statements, which speak only as of the date made. DermTech does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.
What is the DermTech Melanoma Test and its significance?
The DermTech Melanoma Test (DMT) is a non-invasive assay designed to enhance melanoma detection, now recommended for VHA coverage, potentially improving access for millions of Veterans.
How many lives does DermTech cover with its melanoma test?
DermTech's total covered lives amount to approximately 124 million, including 68 million under Medicare.
What does the VHA's coverage recommendation mean for DermTech?
The VHA's recommendation for DermTech's melanoma test increases its accessibility, potentially boosting market adoption and revenue.
What is the negative predictive value (NPV) of the DMT?
The DMT has a greater than 99% negative predictive value, indicating high accuracy in ruling out melanoma when test results are negative.
When will the DermTech Melanoma Test be available to Veterans?
DermTech anticipates making its melanoma test widely available to Veterans through the VHA in the upcoming months.
